FDA Approves Inavolisib for PIK3CA-Mutated HR+/HER2− MBC

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

In the approval trial, Genentech’s PI3K inhibitor doubled progression-free survival compared with placebo.
Medscape Medical News